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Outcomes of psychotic disorders are associated with high personal, familiar, societal 
and clinical burden. There is thus an urgent clinical and societal need for improving 
outcomes of psychosis. Recent advances in research knowledge have opened new 
opportunities for ameliorating outcomes of psychosis during its early clinical stages. 
This paper critically reviews these opportunities, summarizing the state-of-the-art 
knowledge and focusing on recent discoveries and future avenues for first episode 
research and clinical interventions. Candidate targets for primary universal 
prevention of psychosis at the population level are discussed. Potentials offered by 
primary selective prevention in asymptomatic subgroups (stage 0) are presented. 
Achievements of primary selected prevention in individuals at clinical high risk for 
psychosis (stage 1) are summarized, along with challenges and limitations of its 
implementation in clinical practice. Early intervention and secondary prevention 
strategies at the time of a first episode of psychosis (stage 2) are critically discussed, 
with a particular focus on minimizing the duration of untreated psychosis, improving 
treatment response, increasing patients’ satisfaction with treatment, reducing illicit 
substance abuse and preventing relapses. Early intervention and tertiary prevention 
strategies at the time of an incomplete recovery (stage 3) are further discussed, in 
particular with respect to addressing treatment resistance, improving well-being and 
social skills with reduction of burden on the family, treatment of comorbid substance 
use, and prevention of multiple relapses and disease progression. In conclusion, to 
improve outcomes of a complex, heterogeneous syndrome such as psychosis, it is 
necessary to globally adopt complex models integrating a clinical staging framework 
and coordinated specialty care programmes that offer pre-emptive interventions to 
high-risk groups identified across the early stages of the disorder. Only a systematic 
implementation of these models of care in the national health care systems will 
render these strategies accessible to the 23 million people worldwide suffering from 
the most severe psychiatric disorders. 
 
Key words: Psychosis, schizophrenia, psychosis risk, clinical high risk, first episode 
psychosis, universal prevention, selective prevention, indicated prevention, 
outcomes, clinical staging 
Psychotic disorders such as schizophrenia are common, with 23.6 million 
prevalent cases worldwide in 20131. One in two people living with schizophrenia 
does not receive care for the condition2. The recovery rates (one in seven3) and 
associated disability (11th cause of disability worldwide in 20131) following a first 
episode of psychosis have not improved over the past seventy years under routine 
clinical care1,3. Although existing psychopharmacological treatments alone can 
reduce some symptoms, they have little impact on the outcome of the illness4.  
The annual national costs for the schizophrenia population ranged from US$ 94 
million to US$ 102 billion worldwide, up to 1.65% of the gross domestic product5. 
Furthermore, risk of all-cause mortality for psychotic disorders is twice (risk ratio 
2.54) that of the general population6. There is thus an urgent clinical and societal 
need for improving outcomes of psychosis.  
Recent advances in research knowledge have opened new opportunities for 
ameliorating outcomes of psychosis during the critical periods surrounding the first 
episode of the illness (about 2 years before7 and 3 years after8 the onset). In this 
paper, we critically review these opportunities, summarizing the state-of-the-art 
knowledge and focusing on recent discoveries and future avenues for first episode 
research and clinical interventions.  
As a conceptual framework we will adopt a revised version of the clinical staging 
model9 (Table 1). We will mostly focus on non-affective psychoses, although some 
issues can also be applied to the other types of psychoses. 
 
 
PRIMARY PREVENTION  
 
Mental health promotion aims to promote positive mental health by increasing 
psychological well-being, competence and resilience, and by creating supporting 
living conditions and environments. It is not addressed in the present paper.  
Primary prevention aims to reduce the incidence of symptoms and ultimately of 
mental disorders10. The three categories of primary prevention identified by the World 
Health Organization (WHO)11 are: universal prevention, targeting the general public 
or a whole population group that has not been identified on the basis of individual 
risk; selective prevention, targeting individuals or subgroups of the population whose 
risk of developing a mental disorder is significantly higher than the rest of the 
population; and indicated prevention, targeting high-risk individuals who are identified 
as having minimal but detectable signs or symptoms foreshadowing mental 
disorders.  
Universal prevention of psychosis 
 
Universal primary prevention must take the form of a safe population-wide 
intervention that promotes normal development. Research in this area is still in its 
infancy, because no established pathophysiological mechanisms to be targeted have 
been validated12.  
A recent pioneering, randomized placebo-controlled clinical trial of dietary 
phosphatidylcholine supplementation was conducted in a small sample of healthy 
pregnant women, starting in the second trimester and continuing through the third 
postnatal month13. The intervention aimed at correcting delays in cerebral inhibition 
that may develop perinatally, as indexed by electrophysiological biomarkers. The 
intervention was free of significant side effects and showed proof of concept efficacy.  
Although larger studies need to be conducted to validate these initial findings, 
future research in this field is warranted over the next decade. Promising research 
candidates for the universal prevention of psychosis and the supporting evidence, 
which awaits future replication, are listed in Table 2. 
 
Asymptomatic genetic risk (stage 0) 
 
The staging perspective (Table 1) provides a framework for research and 
conceptualization of earlier premorbid interventions to alter the developmental 
pathway to first-episode psychosis. Selective interventions in this stage could target 
familial, perinatal, social or later environmental risk factors before symptoms and 
help-seeking behaviour manifest14, such as those listed in Table 3.  
Although this is an exciting area for future research, currently there are no robust 
and effective preventive strategies to reduce the risk of psychosis in asymptomatic 
individuals exposed to these environmental risk factors15. For now, the primary viable 
strategy is to use the family high-risk approach (selecting offspring of individuals with 
schizophrenia), even though this approach will only yield roughly 10% of the 
individuals from these families who will develop psychosis15.  
Improving mental health literacy in these at-risk populations may represent an 
effective pragmatic strategy to help prevent or facilitate earlier intervention in 
psychosis (Table 1). 
 
 
 
 
Clinical high risk for psychosis (CHR-P, stage 1a-c) 
 
State of the art 
 
The introduction of specific semi-structured interviews16-18, about two decades 
ago19, for the ascertainment of signs and symptoms suggestive of psychosis-risk 
states has allowed the identification of individuals at clinical high risk for the 
development of psychosis (CHR-P) before full symptoms manifest20. These 
individuals are functionally impaired compared to matched controls at baseline21 and 
have an up to 20% 2-year  risk (95% CI: 17%-25%) of developing psychosis22.  
Their risk peaks in the first two years23 and is specific for the development of 
psychotic disorders but not for emerging non-psychotic disorders24,25. However, less 
than half of those who will not develop psychosis will eventually remit (35% of the 
baseline cohort)26, since persistent comorbidities (that were already present at 
baseline27-29) and functional impairment are frequently observed at follow-up28.  
Indicated interventions through specialist CHR-P provision have been 
recognized as an important component of clinical services for early psychosis 
intervention30-32 – see, for instance, the guidelines of the UK National Institute for 
Health and Care Excellence (NICE)33, and the Access and Waiting Time (AWT) 
standards of the UK National Health Service30.  
Conceptually, although most of CHR-P individuals (73%) would present with 
some comorbid DSM-IV diagnosis at baseline27,34, the intervention is still considered 
preventive35 (indicated) since these individuals are selected on the basis of having 
early signs or symptoms of psychosis risk.  
Selective interventions in CHR-P people may improve the outcome of first- 
episode psychosis through the following mechanisms: a) delayed or prevented onset 
of a first episode; b) better engagement with services and reduced comorbidity; c) 
reduced duration of untreated psychosis (DUP); and d) improved early detection and 
amelioration of the severity of first-episode cases (secondary prevention). 
Meta-analysis of randomized controlled trials in CHR-P individuals suggests that 
short-term (6-12 months) psychological interventions can halve the risk of illness 
onset at 12 months36. However, the preventive effect is not sustained over a longer 
period of time (24 months and longer); so, these findings should be interpreted 
cautiously and may indicate a delayed rather than prevented psychosis onset. No 
trials have investigated whether long-term provision of focused interventions may 
result in sustained benefits. Furthermore, the three largest studies of preventive 
interventions in individuals at ultra-high risk for psychosis have turned out to be 
negative, possibly because of low power37-39. At the moment, there are no approved 
interventions that have been shown to reliably alter the long-term course of the 
disorder12. 
CHR-P services are effective in improving trust and engagement40, with high 
satisfaction of users. Furthermore, since most CHR-P people present with comorbid 
disorders that are not severe enough to be accepted and treated by generic mental 
health services, CHR-P services may also improve these problems as well as 
provide vocational support and reduce family stress. 
Patients who engage with CHR-P services and who will later develop the 
disorder show a substantial reduction of their DUP (11 days on average) compared 
to patients who do not present to clinical services until the first episode 
(approximately 1 year on average)41. Compared to patients accessing first episode 
services, patients who presented in the CHR-P stage are also less likely to require 
admission following the onset of psychosis (46% vs. 68%) and less likely to require a 
compulsory admission in the short-term (30% vs. 62%)41.  
Finally, the presence of CHR-P services may have extended benefits for the 
identification of first-episode cases and for secondary prevention. In fact, about one-
third of patients referred to CHR-P services have already developed a first episode of 
psychosis at the time of initial contact40. First-episode patients presented to CHR-P 
service spent fewer days in hospital (less than 17), had a shorter referral to diagnosis 
time (–74.5 days), a lower frequency of admission (incidence rate ratio = 0.49), and a 
lower likelihood of compulsory admission (odds ratio = 0.52) compared to patients 
who were first diagnosed by first episode services40. However, theses findings may 
be confounded by a selection bias, which is discussed below here. 
 
Challenges and future advancements 
 
Even assuming that an effective preventive treatment altering the course of the 
illness may be discovered in the next generation of interventional studies, the overall 
impact of treating CHR-P individuals on the outcomes of first-episode psychosis is 
still undetermined. This is mostly due to the fact that the potential benefits of the 
primary prevention during the CHR-P stage are practically limited by the difficulty to 
identify and treat all the individuals who are at risk of developing the disorder.  
 
How should CHR-P individuals be recruited from secondary mental health services? 
 
Current guidelines recommend that the CHR-P assessment should be primarily 
offered to individuals who are “already distressed by mental problems and seeking 
help for them”42. These individuals represent an exceptional window of opportunity 
for preventive interventions as they are already in contact with secondary mental 
health services. Unfortunately, only 5.19% of the total cases of emerging first-
episode psychosis among patients accessing secondary mental health services are 
detected and under the care of CHR-P services that had been well established (10 
years before) in the local national health system.  
This result is highly disturbing, as it indicates that the overall real-world impact of 
CHR-P detection and treatment for improving the outcomes of first-episode 
psychosis is minimal, missing 95% of individuals who will eventually develop 
psychosis. Thus, it seems crucial to optimize the proportion of individuals at risk of 
developing psychosis who are referred to CHR-P services. Individualized risk 
estimation e-tools that are based on easily collectable variables have recently been 
developed and externally validated. Since the vast majority (91%) of patients referred 
to first episode services had a first point of contact within secondary mental health 
care43, the use of these tools can substantially extend the benefits of preventive 
interventions to most at-risk individuals and eventually result in a massive impact for 
the improvement of first-episode psychosis outcomes.  
 
How should CHR-P individuals be recruited outside clinical samples? 
 
The use of the CHR-P approach outside clinical samples or for screening 
purposes is not recommended, because its low ability to rule in psychosis16 produces 
a substantial dilution of risk enrichment44, leading to underpowered clinical trials39 
and questionable clinical relevance for preventive interventions16,45-47. For example, 
using CHR-P assessment in the general non-help-seeking adolescent population is 
associated with a 2.5-year risk of psychosis onset of 2% only48.  
At the same time, it seems important to continue exploring the usefulness of an 
extended use of CHR-P assessment to populations not accessing mental health 
services in order to improve detection of at-risk cases. Possible solutions may 
include the use of meta-analytical Fagan’s nomogram16 or stratification models46 that 
have recently been made available to estimate the overall risk enrichment of samples 
undergoing CHR-P assessment.  
A complementary approach may be based on the use of sequential testing 
methods49. The sequential use of screening instruments and CHR-P assessment in 
non-help-seeking adolescents from the general population may identify individuals 
who are at potential risk of developing psychosis in the following years50. Sequential 
testing is in line with the clinical staging model and can be further enhanced by front-
line primary care youth mental health models developed to facilitate the access of 
young people from the school and community51 (see https://www.headspace.org.au).  
Innovative strategies to identify non-help-seeking individuals at risk of psychosis 
can also involve the use of e-health technologies, for example based on semantic 
analysis of social media postings.  
 
Can we provide stratified treatments to the CHR-P subgroups? 
 
Future advances could also develop stratified preventive treatments targeting 
the different CHR-P clinical stages (a, b or c), that may have different characteristics 
with respect to underlying disease processes and prognosis52. On the basis of the 
increasing risk (clinical stage 1a: 3% at 2 years22; clinical stage 1b: 19% at 2 years22; 
clinical stage 1c: 39% at 2 years22 and 51% at more than 3 years53), and symptoms 
severity54 (individuals in the clinical stage 1c would formally meet the ICD criteria for 
a brief psychotic disorder55), preventive interventions for the clinical stage 1a can be 
supplemented by specific psychological therapies and individual psychoeducation for 
the clinical stage 1b.  
These treatments may be further supported by a more intensive or close-in 
monitoring for the clinical stage 1c, which is characterized by short-lived and self-
remitting psychotic episodes lasting few weeks only (e.g., less than 4 weeks)53. In 
line with the clinical staging model, the stage 1b is less severe compared to patients 
experiencing a first episode of schizophrenia (clinical stage 2), who do not 
spontaneously remit from their symptoms without antipsychotic treatment and who 
show substantial higher risk of relapses53. 
 
 
EARLY INTERVENTION AND SECONDARY/TERTIARY PREVENTION  
 
Full threshold first-episode psychosis with early recovery (stage 2) 
 
State of the art 
 
The stage 2 encompasses the acute phase or crisis, that is characterized by 
florid psychotic symptoms (sustained symptoms lasting four weeks or more as 
suggested by the NICE Quality Standard 10256), followed by an early recovery phase 
or post-acute phase observed in the first 6-12 months following the acute episode.  
Recovery is usually operationalized as concurrent clinical remission – less than 
mild symptoms at the Positive and Negative Syndrome Scale (PANSS) (≤3), the 
Scale for the Assessment of Positive Symptoms (SAPS)/Scale for the Assessment of 
Negative Symptoms (SANS) (≤3), or the Brief Psychiatric Rating Scale (BPRS) (≤2), 
sustained for at least 6 months57 – and functional remission (proper social functioning 
in the main domains of everyday life)58. Selective interventions during stage 2 may 
improve the outcome of first-episode psychosis through the following mechanisms: a) 
DUP reduction; b) improvement of treatment response; c) improved well-being, 
functioning and social skills with reduction of burden on the family; d) treatment of 
comorbid substance use; e) secondary prevention of disease progression. 
A long DUP is associated with poor general symptomatic outcome, more severe 
positive and negative symptoms, lesser likelihood of remission, and poor social 
functioning and global outcome, but not employment, quality of life or hospital 
treatment59. The meta-analytical correlations are small in magnitude (r=0.13-0.18), 
yet robust59. Since the majority of DUP is accounted for by delays in accessing early 
intervention services and help-seeking60, at least in the UK, it is a modifiable factor 
even during the clinical stage 2. Community psychosis awareness campaigns, 
including publicity and community engagement integrated with a specific youth 
mental health direct care pathway, can halve the DUP (mean 285 days) compared to 
detection as usual (mean 104 days)60.  
Beyond the impact on DUP, intervention in the clinical stage 2 can be associated 
with substantial improvements in treatment response. A systematic research of the 
literature summarizing the results of randomized controlled trials of integrated 
multicomponent early intervention services for patients experiencing a first episode of 
psychosis is presented in Table 4. The multicomponent interventions were mostly 
based on the comprehensive use of antipsychotics61-68, individual psychological 
treatments61-63,65-68, family61-66,68 and vocational61,62,64,65,68 support. Small trials showed 
minimal beneficial effects or no effects at all on clinical outcomes62,63,69. Larger trials 
showed a significant short-term (i.e., up to 24 months) improvement of treatment 
response under specialized integrated early interventions compared to standard 
community care. The improved response to the comprehensive treatments was 
characterized by lower disengagement from care61,64,65; reduction of positive63,64,68, 
negative63,64 and total65,66,68 psychotic symptoms; reduced hospitalization61,68, lower 
dosages of antipsychotic medications64, and improved functioning66.  
Specialized interventions during the clinical stage 2 are associated with higher 
patients’ satisfaction with treatment64 and improved personal well-being65,66, 
characterized by better sense of purpose, motivation, curiosity and emotional 
engagement65. These improvements translated into better quality of life65 and greater 
involvement in school and work65,68, with an overall reduced burden to the family64. 
Family interventions for first-episode psychosis are an integral component of 
treatment, but they can have beneficial effects even as standalone treatment, with 
greater 12-month improvements in family burden and caregiving experience, 
reductions in severity of psychotic symptoms and duration of re-hospitalizations70.  
The detrimental impact of illicit substance abuse on the long-term outcome of 
psychosis is well known, with a dose-dependent association71. Available trials 
confirm that it is possible to reduce substance abuse in first-episode psychosis 
through specialized integrated early intervention services64. Ongoing randomized 
controlled trials are directly investigating the effectiveness of a behavioural 
intervention for reducing cannabis use among young people receiving treatment from 
early intervention services72,73. 
Finally, interventions in this phase are crucial for the secondary prevention of 
illness progression to clinical stage 3, in particular to prevent relapse into a second 
episode of psychosis (3a). This is significant, because relapse interferes with the 
social and vocational development of individuals suffering from a first episode of 
psychosis, which has an impact on long-term outcomes74.  
 
Challenges and future advancements 
 
Although specialized first episode services that provide a comprehensive care 
can significantly improve outcomes of first-episode psychosis, and their 
implementation is overall recommended75, there are some significant challenges.  
 
Are specialized integrated early intervention services effective in preventing 
relapses? 
 
Despite the benefits yielded by specialized integrated early intervention services, 
many patients still have an increased risk of relapsing into a second episode of 
psychosis following an initial recovery (clinical stage 3a). Criteria for relapse vary 
across studies, but readmission to a psychiatric hospital is the most common 
definition of psychotic relapse in the existing literature76.  
Since randomized controlled trials provide the gold standard methodology for 
evaluating interventions for relapse prevention, we have updated an earlier meta-
analysis that included only three trials investigating the risk of relapse/admission to 
psychiatric hospital under specialized early intervention services, compared to 
standard care77. We now include 12 trials stratified for different time points, as 
indicated in Table 4.  
We found that relapse rates under treatment usually were 25% (95% CI: 7%-
49%) at 9 months, 48% (95% CI: 30%-65%) at 24 months, and 76% (95% CI: 53%-
90%) at more than 10 years, while under the specialized integrated early intervention 
services they were 23% (95% CI: 13%-36%) at 9 months, 37% (95% CI: 18%-59%) 
at 24 months and 54% (95% CI: 36%-70%) at more than 10 years.  
Figure 1 shows that there was no meta-analytical evidence that specialized 
integrated early intervention services can substantially improve the odds ratio for 
having a relapse compared to standard care, at any time points. These negative 
findings are in line with naturalistic studies, showing that about 50% of first-episode 
non-affective psychosis relapse at least once (clinical stage 3a), while 34% had 
multiple relapses (clinical stage 3b). Adherence (odds ratio 2.9) and schizophrenia 
diagnosis (odds ratio 2.2) were the most robust predictors of the first relapse78.  
These findings are also in line with the lack of stringent evidence for a robust 
effect of antipsychotics on relapse prevention in the long-term and with meta-
analyses indicating that the overall rate of long-term recovery following a first episode 
of psychosis has not improved much worldwide over the past decades3. There is still 
much to be done to develop effective integrated treatments for tertiary relapse 
prevention in early psychosis. 
 
Should we use long-acting injectable antipsychotic earlier? 
 
International treatment guidelines for first-episode psychosis recommend 
antipsychotic medication maintenance for at least 1-2 years to prevent relapse79. The 
most robust meta-analysis of randomized controlled trials of antipsychotics in first-
episode patients showed 26% risk of relapse in the treatment group at 1 year, 
compared to 61% in the placebo group at 1 year (risk ratio = 0.47)80.  
Since antipsychotics are effective in the short-term to prevent relapse, and non-
adherence is a modifiable risk factor, it seems justifiable to introduce the use of long-
acting injectable antipsychotics (LAIs) earlier in the treatment of psychosis, during 
the clinical stage 281. LAIs are superior to placebo not only for the prevention of 
relapse but also for the reduction of symptoms in acutely ill patients with established 
psychosis81.  
However, seven independent meta-analyses of available randomized controlled 
trials, including one conducted in recent-onset psychosis (including only three trials 
enrolling patients with a diagnosis of psychosis within 1-5 years)82, found no 
evidence that LAIs are associated with better efficacy on relapse prevention, 
compared to oral antipsychotics83-88.  
It is possible that randomized controlled trials might enrol patient samples that 
are not representative of real-world clinical practice. In fact, meta-analyses of studies 
comparing LAIs vs. oral antipsychotics in the same patients, that better reflect real-
world efficacy, found strong evidence for LAIs superiority on preventing hospital 
admission (risk ratio = 0.43)89. Furthermore, since the available trials have been 
mostly conducted in chronic patients or in patients with few years of active psychosis, 
the actual efficacy of LAIs in patients with a first episode of psychosis (clinical stage 
2) is undetermined. In general, LAIs are similar to one another in terms of relapse 
prevention81.  
Using LAIs in first episode patients with clear risk factors for relapse – such as a 
diagnosis of schizophrenia, non-adherence to oral antipsychotics, comorbid 
substance misuse and poor insight – may thus substantially improve outcomes of 
first-episode psychosis.   
 
For how long should early intervention services be offered? 
 
Beyond relapse prevention, most trials indicated that the benefits provided by 
early intervention services were attenuated over the long term90-92, at more than 2-
year follow-up, although these findings may be due to insufficient power. It is likely 
that the positive effects of intensive early treatment are sustained only if patients 
continue to receive specialized services (though at what intensity/frequency remains 
a question).  
A recent trial compared a 3-year provision of specialized services versus a 2-
year provision of the same. The extended year was associated with significant 
benefits on negative and positive psychotic symptoms, as well as on functioning67. 
This also aligns with the clinical staging model, wherein symptom resolution and 
clinical stabilization take place at an earlier stage followed by gradual functional 
improvement, which occurs later and requires substantially longer to achieve.  
Discharging first-episode patients back to primary care or poor morale generic 
mental health services that focus heavily on patients with persistent illness, after 1-2 
years of specialized early intervention care, is likely to result in the erosion of the 
initial advantages and gains and is thus unlikely to change their long-term recovery 
outcomes.  
Longer-term early intervention services spanning the entire critical period of 5 
years8 are under development93. A subset of cases will almost certainly need longer- 
term expert care. In the context of competing demands and budgetary constraints, it 
is important to note that the costs for comprehensive specialized integrated care are 
exceeded by its benefits, relative to standard community care94-96.  
 
Schizophrenia spectrum vs. affective spectrum first episode psychosis: does it make 
any difference?  
 
Formulating a specific ICD or DSM diagnosis of psychosis at the time of the first 
contact with the first episode services is challenging, because the clinical features 
are relatively non-specific. However, the NICE recommendation 1.3.4.3 for first-
episode psychosis clearly indicates that if the patient’s presentation suggests an 
affective rather than schizophrenia spectrum psychosis, different clinical guidelines 
(e.g., those for bipolar disorder or for depression) should be followed at least for 
psychopharmacological treatments79.  
A meta-analysis conducted in 14,484 first-episode patients, with an average 
follow-up of 4.5 years, found a high prospective diagnostic stability for schizophrenia 
spectrum psychoses (0.93; 95% CI: 0.89-0.97) and for affective spectrum psychoses 
(0.84; 95% CI: 0.79-0.89), which is comparable to other clinical diagnoses in 
medicine97. In line with the clinical staging model, the retrospective diagnostic 
stability was low for both spectra (0.60), indicating that many first-episode patients 
who receive a non-specific diagnosis of psychosis (e.g., psychosis not otherwise 
specified) will eventually develop schizophrenia or affective psychoses97. Therefore, 
having a baseline diagnosis of schizophrenia spectrum or affective spectrum 
psychotic disorder may still have significant clinical impacts98.  
Schizophrenia features are strong predictors of poor long-term outcomes (e.g., 
at 3 years99 and 10 years100-102) in first-episode patients, with odds ratio ranging from 
5.70 to 8.86102. An initial diagnosis of schizophrenia has been associated with higher 
risk of relapse at 3 years (odds ratio 2.7)78. The worse prognostic outcome of an 
initial schizophrenia diagnosis has been confirmed even in modern specialized 
integrated early intervention services that were offering state-of-the-art treatments to 
improve outcome for first-episode psychosis78,102,103. However, when communicating 
with patients, it may be preferable to use the broader term psychosis rather than 
schizophrenia, to fully reflect the possibility of plastic and heterogeneous outcomes. 
 
For how long should we treat remitted patients with antipsychotics? 
 
Because evidence is robust for the effectiveness of antipsychotic medication in 
reducing the short-term risk of relapse, it would seem reasonable to recommend 
medication maintenance for all first-episode individuals. However, the long-term 
efficacy of antipsychotics for relapse prevention is less established. Furthermore, 
since treatment disengagement is common early in the illness and is largely patient-
driven104, more effective alternatives could be considered105. Finally, there is 
increasing concern that cardiometabolic risk factors and abnormalities are present 
early in the illness, and related to the underlying illness, unhealthy lifestyle and 
antipsychotic medications106, as well as subtle extrapyramidal symptoms107.  
As a consequence of these considerations, the long-term use of antipsychotic 
medications has been recently questioned108 and discontinuation of antipsychotic 
medication after 1-2 years is partially recommended by some clinical guidelines109. 
Two recent trials have investigated this issue, comparing treatment maintenance 
versus reduction/discontinuation strategies. In the short term (within the first 3 years), 
the risk of relapse was twice in the reduction/discontinuation group compared to the 
maintenance group107,110. However, in the longer term (at 7 years), the risk of relapse 
was comparable (62% in the reduction/discontinuation group vs. 69% in the 
maintenance group)107.  
Despite some important methodological limitations98, it was additionally found 
that recovery and functional remission rates in the reduction/discontinuation group 
were twice those seen in the non-dose reduction/discontinuation group107. 
Importantly, the patients included in these trials had all experienced a clinical or 
functional remission that was sustained for six107 or 18110 months (i.e., clinical stage 
2). Discontinuing antipsychotic treatment before remission is achieved (e.g., for the 
clinical stage 3) is associated with higher time to remission and later risk of 
relapse111,112.  
Overall, these findings indicate that the effect of antipsychotics is mostly 
symptomatic and unlikely to change the underlying course of the disorder, raising 
suspicion that these drugs may delay but not actually prevent relapses12. In fact, 
longer treatment periods with antipsychotics before withdrawal are not associated 
with reduced risk of relapse105, with a rapid return of symptoms in the relapse 
episode to severity levels similar to those in the first psychotic episode105.   
On the basis of the existing conflicting evidence, treatment reduction may be a 
stage 2 specific option only for the subset of patients who had achieved a clinical 
remission57 and are not at high risk of relapse. The challenge would be to identify 
these low-risk individuals prior to considering treatment reduction113. Future research 
is thus needed to develop reliable stratification models for these patients according to 
the most robust risk factors for relapse: longer duration of untreated psychosis, male 
gender, poor baseline functioning and educational status, and a diagnosis of 
schizophrenia114,115.  
A recent meta-analysis indicated that the risk of relapse in patients diagnosed 
with schizophrenia who have achieved a clinical remission and then discontinued 
antipsychotic medications was 78% at 24 months and 84% at more than 36 
months53. Accordingly, it has been suggested to exclude from treatment 
discontinuation/reduction strategies first-episode patients who have been diagnosed 
with schizophrenia at baseline114.  
However, future replication trials are required before treatment discontinuation/ 
reduction can be safely implemented in clinical practice. A viable solution could be to 
use psychological treatments rather than placebo in both arms of a future 
discontinuation/reduction vs. maintenance trial, which may be an acceptable and 
effective alternative for patients who have chosen not to take antipsychotic drugs116. 
 
Incomplete recovery from first episode of psychosis (stage 3) 
 
State of the art 
 
The critical period after the onset of psychosis extends to the clinical stage 3. 
There are three forms of incomplete recovery: a) recovery is initially achieved but 
then followed by a relapse (clinical stage 3a); b) initial recovery is followed by 
multiple relapses (clinical stage 3b); c) premorbid functional or symptoms levels are 
never fully reached (clinical stage 3c).  
Selective interventions during stage 3 may improve the outcome of first-episode 
psychosis through the following mechanisms: a) addressing treatment resistance; b) 
improving well-being and social skills with reduction of burden on the family; c) 
treatment of comorbid substance use; d) tertiary prevention of multiple relapses and 
disease progression. 
The failure to respond to two different antipsychotics, at therapeutic doses and 
for a sufficient duration117 means that a person meets the criteria for treatment 
resistance, and may thus be in the clinical phase 3c. Approximately 30% of patients 
with first-episode psychosis manifest a minimal response to antipsychotics118. 
Recognizing treatment resistance earlier and treating these cases with clozapine119 
at this stage could produce larger benefits in several domains of outcomes, because 
of the greater retention of patients' personal and social agency73,120,121.  
Early interventions that can improve the well-being, functioning and social skills 
with reduction of burden on the family as well as treat comorbid substance use are 
similar to those described for the clinical stage 2. 
Although it has been suggested that acute psychotic exacerbations represent 
active periods of a morbid process that leads to disease progression (the “neurotoxic 
hypothesis of psychosis”), to date there is limited empirical evidence to support 
illness progression after each relapse105. The mechanisms of toxicity have not been 
described122 and supporting evidence is conflicting123. On the one hand, based on 
limited data, times to remission are significantly longer for the second and third 
episodes124; treatment discontinuation125 and the effective dose126 are higher during 
the subsequent episodes compared to the first one (suggesting reduced 
effectiveness of antipsychotics when reintroduced after illness recurrence); and 
relapse duration (but not frequency) is associated with gray matter alterations127. On 
the other hand, patients’ symptoms return to baseline with resumption of 
antipsychotic medication after the relapse110, and the pattern of treatment response 
across single episode and multiple episodes patients is not different and highly 
variable125,128. For example, emergent treatment failure after relapse is evident in 
16% of the first-episode and 14% of the multi-episode samples respectively125,128, 
replicating an earlier finding that 1 in 6 patients failed to recover from each of their 
first four relapses, irrespective of which relapse it was129. Finally, a subset of patients 
(23%) can even be treatment resistant at the time of illness onset, even before the 
first relapse130.  
It is important to note that, beyond the controversies regarding disease 
progression after each relapse, it is clear that each relapse is a traumatic experience 
associated with potentially serious psychosocial and functional consequences that 
are impacting the quality of life of the patient and the caregiver. Unfortunately, no 
clear interventions have been developed and validated for the tertiary prevention of 
disease progression from stage 3a to stage 3b (prevention of relapse recurrences), 
because second relapses are not consistently associated with robust modifiable risk 
factors such as non-adherence78. Similarly, there are no approved treatments to 
prevent progression to clinical stage 4. Overall, these data are in line with the limited 
evidence for substantial protective effects of antipsychotics on relapse prevention in 
the long term and highlight a clear need for further prospective research elucidating 
the role of relapse on illness progression in early psychosis. 
 
 
 
Challenges and future directions 
 
A new test to identify non-response to antipsychotic and reduce delay to clozapine 
usage 
 
Recent studies suggest that among treatment-resistant first-episode 
schizophrenia patients, 70% never experienced any symptomatic remission from the 
time of their first presentation, while 30% had achieved a symptomatic remission 
before developing treatment resistance during the first 5 years of illness130. 
Therefore, for the majority of cases, treatment resistance could be most appropriately 
addressed with clozapine at an early stage of its presentation, particularly given that 
early treatment with clozapine is effective119, and that worse outcomes are seen with 
a delayed use of the drug131. In standard mental health services, the mean delay in 
initiating clozapine is 4 years132.  
A further possibility to accelerate the use of clozapine for treatment-resistant 
patients may be to use a diagnostic test to predict non-response to antipsychotics. A 
meta-analysis of 34 studies (N=9,460) found that a <20% PANSS or BPRS reduction 
at week 2 of antipsychotic treatment predicted non-response at 12 weeks, with a 
specificity of 86% and a positive predictive value of 90%133. The use of this test in 
early intervention services can facilitate the switch to a second antipsychotic (ideally 
LAIs in patients with risk factors for relapse) and therefore minimize the delay to 
clozapine.  
Another possibility could be to identify treatment-resistant patients at baseline. 
Research in this field is in its infancy, but a recent study suggested that it is possible 
to identify specific predictors of treatment-resistant schizophrenia134. 
 
Can we prevent negative symptoms? 
 
The presence of prominent negative symptoms at baseline is one of the 
strongest predictors of poor outcome in first-episode patients135,136. Negative 
symptoms are twice as likely to become non-responsive to treatments than positive 
symptoms102. A recent meta-analysis found that no available treatment for negative 
symptoms reached the threshold for robust clinically meaningful improvement137.  
Poor social functioning, disorganized symptoms and schizophrenia diagnosis are 
baseline risk factors that can be used to identify first-episode patients at risk of 
developing negative symptoms102. Negative symptoms are also predicted by longer 
DUP138, suggesting that programmes aimed at shortening DUP might reduce the 
prevalence of negative symptoms and improve prognosis of first-episode 
psychosis139.  
 
 
LIMITATIONS OF THE CLINICAL STAGING MODEL 
 
Staging models have been widely adopted in oncology, because stages are 
defined by clear pathophysiological boundaries associated with discrete changes in 
mortality risk and treatment choices136,140. On the contrary, the example of ventricular 
enlargements highlights the lack of utility of current neurobiological measures to 
inform prognosis and treatment decisions in psychosis141. Translation from clinical to 
pathophysiological staging is not yet available in psychosis.  
Variation in cancer severity within a stage (e.g., tumor size or number of 
metastases) has fewer implications for prognosis and treatment than variation 
between stages. This is not the case for psychosis, where high heterogeneity and 
variations within each stage (e.g., stage 2)22 play a substantial role. Additional robust 
evidence is needed to support the incremental clinical utility of the discrete stages 
proposed (e.g., from stage 3 to stage 4)140,142.  
 
 
TOWARDS AN INTERNATIONAL COORDINATED SPECIALTY PROGRAMME 
FOR EARLY PSYCHOSIS  
 
In conclusion, we show here that to improve outcomes of a complex, 
heterogeneous syndrome such as psychosis, it is necessary to globally adopt 
complex models integrating a clinical staging framework and coordinated specialty 
care programmes95 that offer pre-emptive interventions to high-risk groups identified 
across the early stages of the disorder 143.  
It is possible to improve outcomes of first-episode psychosis using stage-specific 
interventions that are comprehensive144, i.e. ranging from the universal prevention of 
psychosis to strategies for overcoming treatment-resistant psychosis, and 
transdiagnostic, i.e. spanning broader spectra during the clinical stage 1 and the 
psychosis spectrum during the clinical phase 2.  
Although we have detailed the key clinical strategies for improving outcomes at 
each clinical stage, it is clear that only a systematic implementation of these cost-
effective94 models of care in the national health care systems will render these 
strategies accessible to the 23 million people worldwide suffering from the most 
severe psychiatric disorders.  
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Table 1  Revised clinical staging model for psychotic disorders and interventions for 
improving the outcomes of first-episode psychosis (FEP) 
 
Clinical 
stage 
Definition Definition in  
clinical staging 
model 
Intervention 
 
0 
 
Asymptomatic genetic 
risk 
 
Premorbid 
 
Selective primary prevention  
Improved mental health literacy 
Family psychoeducation 
1a Negative and cognitive 
symptoms 
CHR-P Indicated primary prevention 
Formal mental health literacy 
Family psychoeducation 
Active reduction of substance misuse 
1b Attenuated psychotic 
symptoms 
CHR-P Indicated primary prevention 
Family and individual psychoeducation 
Active reduction of substance misuse 
Vocational support 
   Psychological therapies 
1c Short-lived remitting 
psychotic episodes  
CHR-P Indicated primary prevention  
As for 1b 
Close-in monitoring  
2 Full-threshold FEP Early full 
recovery 
Early intervention and secondary prevention  
Family and individual psychoeducation 
Psychological therapies 
Active reduction of substance misuse 
Atypical antipsychotics and other medications 
Vocational rehabilitation 
3a Single relapse of 
psychotic disorder 
Late/incomplete 
recovery  
Early intervention and tertiary prevention  
As for 2, but with emphasis on relapse prevention 
and early warning signs 
3b Multiple relapses Late/incomplete 
recovery  
Early intervention and tertiary prevention  
As for 2, but with emphasis on long-term 
stabilization 
3c Incomplete recovery from 
first episode of care 
Late/incomplete 
recovery  
Early intervention and tertiary prevention  
As for 3a; clozapine in case of treatment resistance  
4 Severe, persistent or 
unremitting illness 
Chronicity Maintenance intervention  
As for 3a-c, but with emphasis on social 
participation despite ongoing disability 
 
CHR-P – clinical high risk for psychosis	  
Table 2  Candidate universal interventions for primary prevention of psychosis	  
Intervention Supporting evidence Target 
Perinatal phosphatidylcholine Randomized controlled 
trial13 
Electrophysiological biomarkers of neonatal 
development 
School-based interventions  Randomized controlled 
trials145,146 
Bullying, victimization, pro-bullying 
attitudes, pro-victim attitudes, empathy 
toward victims 
Fetal and neonatal N-acetylcisteine Randomized controlled 
trial147 
Biomarkers of neuroinflammation and 
neuroprotection 
N-3 polyunsaturated fatty acids  Review148 Biomarkers of neuroinflammation 
Vitamins A, D, B-group, folic acid  Original study, meta-
analysis149,150 
Biomarkers of neuroinflammation 
Sulphoraphane Review151 Biomarkers of oxydative stress 
Prebiotics Review152 Microbiota dysbiosis 
School-based interventions Randomized controlled 
trial, review153,154 
Substance abuse 
Exercise training Original studies155-158 Brain plasticity, structure, connectivity, 
cognitive functioning 
Table 3  Some environmental risk factors for psychosis supported by meta-analytical level of 
evidence in the current literature 
  
Type of 
environmental risk 
factor 
Meta-analytical association with psychosis Association measure  
type: mean (95% CI) 
Familial risk factors Parental psychosis159 RR: 1.62 (1.02-2.58) 
Parental affective disorder159 RR: 6.42 (2.20-18.78) 
Old paternal age160 RR: 2.22 (1.46-3.37)a 
Perinatal risk factors Complications of pregnancy161-163 OR: 2.44 (1.13-5.26)b 
Abnormal foetal growth and development161,162 OR: 3.89 (1.40-10.84)c 
Complications of delivery161,162 OR: 2.21 (1.38-3.54)d 
Gestational influenza163 RR: 1.56 (1.05-2.32) 
Season of birth164 OR: 1.07 (1.05, 1.08) 
Social risk factors Ethnic minority165-167 RR: 4.7 (3.3-6.8)e 
First and second generation immigrant status168 IRR: 2.3 (2.0-2.7)f 
Urbanicity169 OR: 2.37 (2.01–2.81) 
Later risk factors Infections170-172 OR: 2.70 (1.34-4.42)g 
Traumatic brain injury173 OR: 1.42 (1.02-1.97) 
Vitamin D deficiency174 OR: 2.16 (1.32-3.56) 
Tobacco abuse175 OR: 2.18 (1.23-3.85) 
Cannabis heavy abuse176 OR: 3.90 (2.84-5.34) 
Childhood trauma and adversity177 OR: 2.75 (2.17-3.47) 
Adult life events178 OR: 3.19 (2.15-4.75) 
Premorbid IQ179,180 OR: 4.78 (3.19-7.13)h 
 
RR – risk ratio, OR – odds ratio, IRR – incidence rate ratio  
aage >55, bgestational age <37 weeks, cbirth weight <2000g, dincubator or resuscitator, eBlack African 
vs. White British, ffirst generation migrants, gtoxoplasma gondii, hIQ<70
 
Table 4  Randomized controlled trials of the effectiveness of specialized integrated early intervention services for first-episode psychosis 
 
Study Intervention Control Treatment 
group (N) 
Control 
group 
(N) 
Follow-
up 
(months) 
Outcome 
Craig et al61   Specialized integrated early 
intervention (antipsychotics, 
cognitive behaviour therapy, family 
counselling, vocational help)  
Treatment as usual in 
community care 
71 73 9 No difference in relapse, reduced 
psychiatric hospitalization and 
disengagement  
Kuipers et 
al62  
Specialized integrated early 
intervention (atypical 
antipsychotics, cognitive 
behavioural therapy, family 
intervention, vocational help)  
Treatment as usual in 
community care 
32 27 24 No significant benefits including 
psychiatric hospitalization 
Grawe et al63, 
Sigrúnarson 
et al90 
  
Specialized integrated early 
intevention (family psychoeducation 
and therapy, home crisis 
management, cognitive behavioural 
therapy, antipsychotics)  
Treatment as usual in 
community care 
30 20 24 
144 
At 24 months, reduced negative 
and positive symptoms; no benefits 
on psychiatric hospitalization or 
recurrences.  
No substantial long-term effects 
Petersen et 
al64  
Bertelsen et 
al91 
Secher et al92 
Specialized integrated early 
intervention (family 
psychoeducation, social skills 
training, antipsychotics) 
Treatment as usual in 
community care 
275 272 24 
60 
120 
At 24 months, improvement on 
positive and negative psychotic 
symptoms, substance abuse, 
treatment adherence; lower dosage 
of antipsychotic medication, higher 
satisfaction with treatment, reduced 
burden to the family; no effect on 
psychiatric hospitalization 
At 60 months, many positive 
effects disappeared; more patients 
living independently 
At 90 months, most positive effects 
had diminished or vanished 
Kane et al65  Specialized integrated early 
intervention (family 
psychoeducation, resilience-focused 
individual therapy, supported 
employment and education, 
antipsychotics) 
Treatment as usual in 
community care 
223 131 24 Reduced disengagement,  greater 
improvement in quality of life, 
wellbeing and total 
psychopathology, greater 
involvement in work and school, 
no effect on psychiatric 
hospitalization 
Ruggeri et 
al66  
Specialized integrated early 
intervention (cognitive behavioral 
therapy, family intervention, case 
management, antipsychotics) 
Treatment as usual in 
community care 
272 172 9 Reduced total symptom severity, 
improved functioning and 
emotional wellbeing; no effect on 
psychiatric hospitalization or 
disengagement 
Srihari et al68    
 
Specialized integrated early 
intervention (antipsychotics, 
family education, cognitive-
behavioral therapy, vocational 
support) 
Treatment as usual in 
community care 
 
60 
 
57 
 
24 
 
Reduced psychiatric 
hospitalization, positive and total 
psychotic symptoms, improved 
vocational engagement, no effect 
on functioning 
Chang et al67  
Chang et al181 
 
3-year specialized integrated early 
intervention (psychosocial 
interventions, cognitive behavioural 
therapy, antipsychotics) 
2-year specialized 
integrated early 
intervention and 1-
year step-down care 
 
82 78 12 Better functioning, reduced 
negative and depressive symptoms 
and disengagement, no effect on 
psychiatric hospitalization 
 
Ando et al69           Specialized integrated early 
intervention  
 
Treatment as usual in 
community care 
 
34 34 9 No effects on disengagement, 
functional remission, psychiatric 
hospitalization, self-harm, suicide 
attempt, social relationship 
NOTE: Weights are from random effects analysis
.
.
.
.
.
.
9 months
Craig et al [61]
Ruggeri et al [66]
Ando et al [69]
 Subtotal  (I-squared = 53.1%, p = 0.119)
12 months
Petersen et al [64]
Subtotal 
24 months
Kuipers et al [62]
Grawe et al [63]
Petersen et al [64]
Kane et al [65]
Srihari et al [68]
Subtotal  (I-squared = 55.5%, p = 0.061)
60 months
Bertelsen et al [91]
Subtotal 
120 months
Secher et al [92]
Subtotal 
144 months
Sigrúnarson et al [90]
Subtotal
Study
0.52 (0.26, 1.03)
1.08 (0.64, 1.84)
1.97 (0.51, 7.56)
0.91 (0.47, 1.75)
0.73 (0.44, 1.22)
0.73 (0.44, 1.22)
0.41 (0.13, 1.27)
0.50 (0.16, 1.59)
1.06 (0.70, 1.59)
1.16 (0.75, 1.82)
0.39 (0.18, 0.86)
0.75 (0.47, 1.18)
0.90 (0.64, 1.26)
0.90 (0.64, 1.26)
1.26 (0.85, 1.87)
1.26 (0.85, 1.87)
0.36 (0.09, 1.36)
0.36 (0.09, 1.36)
OR (95% CI)
37.36
45.37
17.27
100.00
100.00
100.00
11.51
11.19
30.28
28.93
18.09
100.00
100.00
100.00
100.00
100.00
100.00
100.00
% weight
  1.0926 10.8
Favors EI Favors TAU
 
 
Figure 1 Meta-analytical odds for relapses (hospital readmission) with specialized 
integrated early intervention services (EI) compared to the odds of relapse with 
standard care (TAU) in the community. Odds ratios smaller than 1 indicate an 
association of reduced relapses with EI, while odds ratios greater than 1 indicate an 
association of reduced relapses with TAU. Weights are from random effects analysis. 
 
